On ECHEMI
Home > Drugs > Ribavirin Injection

Ribavirin Injection

Function and Efficacy

1 Pharmacology Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of many viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. This product does not change the adsorption, invasion and uncoating of viruses, nor does it induce the production of interferon. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus. 2 Toxicological animal experiments have found that this product can induce benign tumors of the breast, pancreas, pituitary and adrenal glands, but its carcinogenicity to humans has not been confirmed. The drug can cause malformations of the head, palate, eyes, jaw, bones and gastrointestinal tract in animals such as hamsters, and reduce the survival of offspring, but primate experiments have not found any effect of the drug on the fetus. Cardiac damage occurred in mice, rats, and monkeys given oral ribavirin at doses of 30, 36, and 120 mg/kg or more for 4 weeks (equivalent to human doses of 4.8, 12.3, and 111.4 mg/kg for a 5 kg child or 2.5, 5.1, and 40 mg/kg for a 60 kg adult).

Ingredients

The main ingredient of this product is ribavirin

Name Description Content CAS NO. Manufacturer
RibavirinIngredients

A broad-spectrum antiviral drug that inhibits the growth of multiple viruses in vitro, including respiratory syncytial virus, influenza virus, hepatitis A virus, and adenovirus. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase, and mRNA guanosine transferase, thereby causing a reduction in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus.

More
36791-04-5 33

Appearance

This product is a colorless clear liquid

Indication

Antiviral drug. Used for viral pneumonia and bronchitis caused by respiratory syncytial virus.

Usage and Dosage

Dilute with sodium chloride injection or 5% glucose injection to a solution containing 1 mg per 1 ml and then slowly drip intravenously. Adults take 0.5 g at a time, twice a day, and children take 10-15 mg/kg per day according to body weight, divided into 2 doses. Each drip should last for more than 20 minutes, and the course of treatment is 3-7 days.

Adverse Reactions

Common adverse reactions include anemia and fatigue, which disappear after stopping the drug. Less common adverse reactions include fatigue, headache, insomnia, loss of appetite, nausea, vomiting, etc., and can cause a decrease in red blood cells, white blood cells and hemoglobin.

Precautions

It is forbidden for people who are allergic to this product and pregnant women. It is not recommended for the elderly.

Special Population Medication

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: Pregnant women are prohibited from using this product. Precautions for the elderly: This product is not recommended for the elderly.

Drug Interactions

This product has an antagonistic effect when used together with zidovudine, because this product can inhibit the conversion of zidovudine into active zidovudine phosphate.

Storage

Keep in a sealed container

Packaging Specification

5ml:500mg

Validity Period

36 months

Manufacturer

Zhejiang Cheng Yi Pharmaceutical Co., Ltd.

  • Founded in:

    2001-06-22
  • Address:

    No. 118, Huagong Road, Dongtou District, Wenzhou
  • Tax NO.:

    913303007303249630
  • Registered Funds:

    327.30432 million yuan
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.